PolyPid Ltd. (NASDAQ:PYPD – Free Report) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of PolyPid in a note issued to investors on Wednesday, May 1st. HC Wainwright analyst B. Pachaiyappan forecasts that the company will post earnings per share of ($0.81) for the quarter. HC Wainwright has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for PolyPid’s Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.48) EPS and Q4 2025 earnings at ($0.40) EPS.
PolyPid (NASDAQ:PYPD – Get Free Report) last posted its quarterly earnings data on Wednesday, February 14th. The company reported ($3.97) EPS for the quarter, missing analysts’ consensus estimates of ($2.17) by ($1.80).
PolyPid Stock Performance
Institutional Trading of PolyPid
An institutional investor recently bought a new position in PolyPid stock. Rosalind Advisors Inc. purchased a new stake in PolyPid Ltd. (NASDAQ:PYPD – Free Report) in the first quarter, according to its most recent filing with the SEC. The fund purchased 415,800 shares of the company’s stock, valued at approximately $1,913,000. PolyPid comprises 1.8% of Rosalind Advisors Inc.’s portfolio, making the stock its 20th biggest position. Rosalind Advisors Inc. owned approximately 8.67% of PolyPid as of its most recent filing with the SEC. Institutional investors own 26.47% of the company’s stock.
PolyPid Company Profile
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
Featured Articles
- Five stocks we like better than PolyPid
- How to Use the MarketBeat Stock Screener
- Appleās Earnings Show Investors Its Strength and Its Weakness
- 3 Healthcare Dividend Stocks to Buy
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- Stock Sentiment Analysis: How it Works
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.